Back to News
Market Impact: 0.2
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies
Source: Business Wire
Healthcare & Biotech
Crossbow dosed the first participant in its Phase 1 trial of CBX-663 for multiple hematologic and solid tumors. The milestone advances the oncology candidate into initial human testing, though efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- RNC Day 1 Kicks off in Dallas
- Xenon at wells fargo healthcare conference: azetukalner launch nears
- Kaplan Fox is Investigating Possible Securities Law Violations against Alignment Healthcare, Inc. (NASDAQ: ALHC)